The adherence and illness perception of patients diagnosed with asthma or chronic obstructive pulmonary disease treated with polytherapy using new generation Cyclohaler
- PMID: 25254009
- PMCID: PMC4171677
- DOI: 10.5114/pdia.2014.45070
The adherence and illness perception of patients diagnosed with asthma or chronic obstructive pulmonary disease treated with polytherapy using new generation Cyclohaler
Abstract
Introduction: The factors influencing adherence of patients diagnosed with asthma and chronic obstructive pulmonary disease (COPD) include the complexity of the therapy, fear of side effects of drugs, method of taking the drug, dosage regimen, polypharmacy, adverse events, knowledge about the essence of the disease and its complications, illness perception and priorities in life, training on the use of the inhaler, the duration of treatment, social support, and drug availability.
Aim: To assess the adherence of patients diagnosed with asthma and COPD treated with polytherapy with fluticasone propionate and formoterol fumarate using the Fantasmino inhaler in relation to primary diagnosis and illness perception as well as patients' and doctors' opinion about this form of therapy.
Material and methods: A questionnaire survey covering adherence, illness perception and opinion about polytherapy using new generation Cyclohaler performed by pulmonologists, allergologists and general practitioners in 3,618 patients with asthma and 2,602 with COPD.
Results: On visit 1, a lower adherence rate was observed in COPD than in the asthma group (72.0% vs. 61.5%; p < 0.01). During the observation, the adherence rate increased significantly in the COPD group, only (61.5% vs. 73.0%; p < 0.01). A negative correlation between total MMAS-8 and BIPQ scores was observed in both study groups (R = -0.15; p < 0.001 and R = -0.24; p < 0.001, respectively). During the observation, a percentage of patients who believed that the administration of the two drugs in a single inhaler considerably facilitates their use increased significantly in both study groups. In addition, an increased percentage of doctors believed that this therapeutic option facilitated education of patients and decreased the number of errors made by the patients.
Conclusions: The illness perception, younger age, disease duration and severity are predictors of adherence to treatment with fluticasone propionate and formoterol fumarate using the Fantasmino inhaler among patients with asthma and COPD. The positive opinion of patients and doctors about administration of fluticasone propionate and formoterol fumarate using the Fantasmino inhaler increased during observation.
Keywords: adherence; asthma; chronic obstructive pulmonary disease; new generation Cyclohaler; polytherapy.
Similar articles
-
Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.Pneumonol Alergol Pol. 2013;81(6):527-36. Pneumonol Alergol Pol. 2013. PMID: 24142782 Clinical Trial.
-
Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β2-agonists in patients with asthma and chronic obstructive pulmonary disease.Postepy Dermatol Alergol. 2021 Oct;38(5):752-760. doi: 10.5114/ada.2020.99945. Epub 2020 Oct 16. Postepy Dermatol Alergol. 2021. PMID: 34849120 Free PMC article.
-
An innovative corticosteroid/long-acting β2-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma.Expert Opin Drug Deliv. 2019 Dec;16(12):1367-1380. doi: 10.1080/17425247.2019.1689957. Epub 2019 Nov 28. Expert Opin Drug Deliv. 2019. PMID: 31752560 Review.
-
Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.Clin Drug Investig. 2012 Jul 1;32(7):439-49. doi: 10.2165/11598840-000000000-00000. Clin Drug Investig. 2012. PMID: 22607479 Clinical Trial.
-
Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.Drugs. 2012 Feb 12;72(3):395-414. doi: 10.2165/11208460-000000000-00000. Drugs. 2012. PMID: 22316354 Review.
Cited by
-
Factors That Influence Adherence to Medication in Adults With Congenital Heart Disease (ACHD).Front Psychiatry. 2021 Nov 24;12:788013. doi: 10.3389/fpsyt.2021.788013. eCollection 2021. Front Psychiatry. 2021. PMID: 34899440 Free PMC article.
-
Factors related to good asthma control using different medical adherence scales in Latvian asthma patients: an observational study.NPJ Prim Care Respir Med. 2017 Jun 20;27(1):39. doi: 10.1038/s41533-017-0042-x. NPJ Prim Care Respir Med. 2017. PMID: 28634371 Free PMC article.
-
Factors related to poor adherence in Latvian asthma patients.Allergy Asthma Clin Immunol. 2020 Mar 4;16:16. doi: 10.1186/s13223-020-0414-6. eCollection 2020. Allergy Asthma Clin Immunol. 2020. PMID: 32158475 Free PMC article.
-
Evidence of the association between adherence to treatment and mortality among patients with COPD monitored at a public disease management program in Brazil.J Bras Pneumol. 2021 Dec 13;48(1):e20210120. doi: 10.36416/1806-3756/e20210120. eCollection 2021. J Bras Pneumol. 2021. PMID: 34909924 Free PMC article.
-
Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol.Patient Prefer Adherence. 2015 Feb 2;9:235-42. doi: 10.2147/PPA.S71535. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 25673975 Free PMC article. Review.
References
-
- Smoliński B, Sybilski AJ, Raciborski F, et al. Prevalence of asthma in children, adolescents and young adults in Poland – results of the ECAP study [Polish] Alergia Astma Immunologia. 2009;14:27–34.
-
- Bednarek M, Maciejewski J, Woźniak M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63:402–7. - PubMed
-
- Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Updated 2013. Available from: http://www.goldcopd.org/
-
- Global Strategy for Asthma Management and Prevention (GINA) Revised 2014. Available from: http://www.ginasthma.com/ - PubMed
-
- Clark NM, Cabana MD, Nan B, et al. The clinician-patient partnership paradigm: outcomes associated with physician communication behavior. Clin Pediatr (Phila) 2008;47:49–57. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources